Stopping immunosuppression after failed kidney transplant
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares what happens when patients with a failed kidney transplant (still in the body) stop their immunosuppressant medicines at 6 months versus continuing them. The goal is to safely prevent your immune system from becoming too sensitive, which can make finding a new donor kidney harder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had at least one kidney transplant that failed and is still in your body for at least 3 months.
- You are currently on dialysis (hemodialysis or peritoneal dialysis) for less than 6 months.
- You are taking the immunosuppressant medicines tacrolimus or cyclosporine along with steroids.
- Your cPRA blood test result is 90% or less.
- You are not pregnant and, if able to have children, agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows older people who received a kidney transplant and are taking a specific immune-suppressing medicine plan (Advagraf/tacrolimus once daily plus mycophenolate and steroids). It may help researchers understand outcomes in real-world patients who match these medication and immune-risk criteria.
This trial tests whether children who had a liver transplant before age 6 can safely stop taking their anti-rejection medicine. It's for children who are doing well — with normal liver function and no signs of rejection or scarring — at least 4 years after transplant.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study is for people whose first kidney transplant has stopped working and who need to start dialysis. The goal is to see if continuing certain anti-rejection medications can help prevent the body from making antibodies that would make it harder to get another transplant in the future.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
Hear when a new Chronic Renal Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.